Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.

NCT Number	NCT07003191
Lead Sponsor	Sun Yat-sen University Collaborators: First Affiliated Hospital, Sun Yat-Sen University, Liaoning Health Industry Group Fushun Mining General Hospital, Liaoning Health Industry Group Benxi Steel General Hospital, Changsha Fourth Hospital, Second Hospital of Shanxi Medical University, The First People's Hospital of Kunshan, Suzhou Ninth People's Hospital, the First Affiliated Hospital of Anhui University of Science and Technology, Mingguang People's Hospital, the People's Hospital Longhua Shenzhen, Affiliated Hospital of North Sichuan Medical College, Yiyang County People's Hospital, THE SECOND PEOPLE'S HOSPITAL, WUHU, The First People's Hospital of Zhangjiagang, Yixing People's Hospital, Shijiazhuang People's Hospital, The First People's Hospital of Guiyang, Lanzhou University Second Hospital, Tiefa Coal Industry Group General Hospital, Shenzhen Hospital of Southern Medical University, The Second Hospital of Shijiazhuang, The Affiliated People's Hospital of Ningbo University, Dongyang People's Hospital, Xiangyang Central Hospital, Li Hui Li Hospital, Nanning Second People's Hospital, Hunan Provincial People's Hospital Ma Wang Dui Branch, Second Affiliated Hospital of Bengbu Medical College, Ruyang County People's Hospital, Kaifeng People's Hospital, Dingzhou People's Hospital, The Second People's Hospital of Changshu, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Dengzhou People's Hospital, Taizhou First People's Hospital, Red Cross Hospital, Hangzhou, China, First People's Hospital of Hangzhou, China Resources Wugang General Hospital, Yiwu Central Hospital, The First People's Hospital of Jiashan County, The First People's Hospital of Tongxiang City, Shaoxing Central Hospital, The First People's Hospital of Jiande City, Beilun District People's Hospital, Huantai County People's Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Shaanxi Hospital of Traditional Chinese Medicine, Zhangjiagang Traditional Chinese Medicine Hospital
Conditions	Type 2 Diabetes
Enrollment	2,600 participants
Start Date	2023-08-02
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-04